SCHEMBL10176219

SCHEMBL10176219

CN(C)CC(=O)Nc1ncc(/C=C2\S/C(=N\c3ccccc3)NC2=O)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 3/20 0.48
POLB P06746 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
MAPT P10636 5/20 0.46
GSK3B P49841 3/20 0.46
IDE P14735 1/20 0.43
LMNA P02545 1/20 0.42
PIM1 P11309 4/20 0.42
DYRK1A Q13627 4/20 0.42
PIM3 Q86V86 4/20 0.42
DAPK3 O43293 3/20 0.42
DYRK3 O43781 3/20 0.42
MAP4K4 O95819 3/20 0.42
CSNK2A1 P68400 3/20 0.42
HIPK2 Q9H2X6 3/20 0.42
CLK4 Q9HAZ1 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653260 0.87 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL653261 0.87 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL649125 0.87 NPC1 (0.54) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL651590 0.87 NPC1 (0.54) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL649238 0.85 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL648656 0.85 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL10176143 0.84 RAB9A (0.50) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL10176233 0.83 NPC1 (0.50) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL651432 0.82 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1
SCHEMBL651433 0.82 NPC1 (0.48) NPC1RAB9APOLBSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 NPC1 1074/4885RAB9A 3157/4885POLB 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.